NEJM Editorial Warns of Downside to ‘Premature’ Consumer Genomics Market | GenomeWeb
NEW YORK (GenomeWeb News) - Several months after the launch of a handful of consumer genomics firms, the medical establishment has fired a volley in what could become a debate between companies trying to bring the genome into the home and physicians trying to treat these newly armed patients.
 
Testing services from companies like 23andMe, Navigenics, Knome, and DeCode Genetics are “premature attempts at popularizing genetic testing,” according to an opinion article in yesterday’s New England Journal of Medicine.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.